Series A · Raised $12.6M · Jul 22, 2026announcement ↗
Brenus Pharma
Backed by
BiotechLyon, Francebrenus-pharma.com ↗
What they do
Brenus Pharma, based in Lyon, develops off-the-shelf in vivo immunotherapies for hard-to-treat solid tumors. Its platform uses engineered, inactivated tumor cells to expose cancer-associated antigens and stimulate immune responses against heterogeneous and treatment-resistant tumors.
Hiring outlook
A $12.6 million Series A in biotech suggests continued hiring in cancer biology, immunology, translational research, process development, and clinical or regulatory operations. The company may also add manufacturing and quality specialists as its candidates move toward clinical development.
Open roles
No open roles on their board right now.